Study participants who took Zepbound also achieved remission or mild obstructive sleep apnea at a greater proportion than the placebo group. These results were observed among those who do and do ...

Snoring affects the quality of life of hundreds of millions of people and can lead to obstructive sleep apnea (OSA ... In one study, 27 people with snoring or mild OSA used the device for ...

The sleep disorder also appears to have direct effects on brain health, a new study shows. People with sleep apnea appear to experience ... compared to 28% who had mild sleep problems and 16% ...

It's currently in phase three trials, but according to phase two results, AD109 offers meaningful improvements to sleep apnea ...

Learn More: What Causes Mild Obstructive Sleep ... gasping for air during sleep, and daytime fatigue are highly suggestive of ...

Share on Pinterest A new study ... people with sleep apnea may have an enlarged hippocampus, which is the area of the brain responsible for memory and learning. Scientists also report that people ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea ... constitutes mild OSA, while more ...

Friday's FDA approval of Zepbound for treating moderate to severe sleep apnea came after the SURMOUNT-OSA phase 3 clinical trials -- two randomized, double-blind, placebo-controlled studies of 469 ...

42% of adults on Zepbound and 50% of adults on Zepbound with PAP therapy experienced remission or mild, non-symptomatic obstructive sleep apnea, compared to 16% and 14% of people who took the ...